A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

Authors :: Michaela Liedtke
Mark DeMario
Sascha A. Tuchman
Eveline Nueesch
Ajay K. Nooka
Hearn Jay Cho
Katharina Lechner
Rakesh Popat
Asher Chanan-Khan
Mark P. Hertzberg
Cristina Gasparetto
Hang Quach
Jacob P. Laubach
Myo Htut
Martin Kornacker
Izolda Franjkovic
Evelyne Chesne
Karthik Ramasamy
Source :: Blood Cancer Journal, Blood Cancer Journal, Vol 11, Iss 9, Pp 1-3 (2021)
Publication Year :: 2021
Publisher :: Nature Publishing Group UK, 2021.

Subjects :: Oncology
medicine.medical_specialty
Hematology
business.industry
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Myeloma
medicine.disease
Lymphoma
BET inhibitor
Internal medicine
Correspondence
medicine
Dose escalation
In patient
Drug therapy
business
RC254-282
Multiple myeloma

Tools